Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001641172-25-004563
Filing Date
2025-04-14
Accepted
2025-04-14 16:05:18
Documents
16
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-ka.htm   iXBRL 10-K/A 313887
2 ex31-1.htm EX-31.1 6864
3 ex31-2.htm EX-31.2 6794
4 ex97-1.htm EX-97.1 72249
  Complete submission text file 0001641172-25-004563.txt   641273

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE gtbp-20241231.xsd EX-101.SCH 3023
6 XBRL LABEL FILE gtbp-20241231_lab.xml EX-101.LAB 35430
7 XBRL PRESENTATION FILE gtbp-20241231_pre.xml EX-101.PRE 23140
18 EXTRACTED XBRL INSTANCE DOCUMENT form10-ka_htm.xml XML 8055
Mailing Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111
Business Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

EIN.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-40023 | Film No.: 25836050
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)